A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder. (28th November 2018)

• Record Type: Journal Article
• Authors: Munkholm, K.; Vinberg, M.; Pedersen, B. K.; Poulsen, H. E.; Ekstrøm, C. T.; Kessing, L. V.
• Is Part Of: Acta psychiatrica Scandinavica. Volume 139:Number 3(2019)
• Page Start: 227
• Page End: 236
• Publication Date: 2018-11-28
• Subjects: bipolar disorder -- biomarkers -- blood -- urine -- gene expression; Psychiatry -- Periodicals; 616.89
• DOI: 10.1111/acps.12983
• Languages: English
• ISSNs: 0001-690X

Abstract

Abstract : Objective: Diagnosis and management of bipolar disorder (BD) are limited by the absence of available laboratory tests. We aimed to combine data from different molecular levels and tissues into a composite diagnostic and state biomarker. Methods: Expression levels of 19 candidate genes in peripheral blood, plasma levels of BDNF, NT‐3, IL‐6 and IL‐18, leukocyte counts, and urinary markers of oxidative damage to DNA and RNA were measured in 37 adult rapid‐cycling patients with BD in different affective states during a 6‐ to 12‐month period and in 40 age‐ and gender‐matched healthy individuals in a longitudinal, repeated measures design comprising a total of 211 samples. A composite biomarker was constructed using data‐driven variable selection. Results: The composite biomarker discriminated between patients with BD and healthy control individuals with an area under the receiver operating characteristic curve (AUC) of 0.83 and a sensitivity of 73% and specificity of 71% corresponding with a moderately accurate test. Discrimination between manic and depressive states had a moderate accuracy, with an AUC of 0.82 and a sensitivity of 92% and a specificity of 40%. Conclusion: Combining individual biomarkers across tissues and molecular systems could be a promising avenue for research in biomarker models in BD.